DE69917074T2 - Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten - Google Patents

Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten Download PDF

Info

Publication number
DE69917074T2
DE69917074T2 DE69917074T DE69917074T DE69917074T2 DE 69917074 T2 DE69917074 T2 DE 69917074T2 DE 69917074 T DE69917074 T DE 69917074T DE 69917074 T DE69917074 T DE 69917074T DE 69917074 T2 DE69917074 T2 DE 69917074T2
Authority
DE
Germany
Prior art keywords
pyridyl
piperidinyl
oxadiazine
dihydro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69917074T
Other languages
German (de)
English (en)
Other versions
DE69917074D1 (de
Inventor
Andrea Jednakovits
Lászlη ÜRÖGDI
Lászlo DENES
István KURUCZ
Ede Marvanyos
Mihály BARABAS
Erno Bacsy
Zsuzsanna Korom
Zoltán NAGY
Lászlo ÜRGE
Jeno Szilbereky
Károly ACSAI
Peter Krajcsi
Csakai
Magdolna TÖRÖK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
Biorex Kutato Fejleszto Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejleszto Kft filed Critical Biorex Kutato Fejleszto Kft
Application granted granted Critical
Publication of DE69917074D1 publication Critical patent/DE69917074D1/de
Publication of DE69917074T2 publication Critical patent/DE69917074T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69917074T 1998-12-14 1999-12-07 Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten Expired - Lifetime DE69917074T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HU9802897 1998-12-14
PCT/HU1999/000095 WO2000035914A1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
DE69917074D1 DE69917074D1 (de) 2004-06-09
DE69917074T2 true DE69917074T2 (de) 2005-05-12

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69917074T Expired - Lifetime DE69917074T2 (de) 1998-12-14 1999-12-07 Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten

Country Status (27)

Country Link
US (1) US6384029B1 (cg-RX-API-DMAC7.html)
EP (1) EP1147105B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002532498A (cg-RX-API-DMAC7.html)
KR (1) KR100661774B1 (cg-RX-API-DMAC7.html)
AT (1) ATE266027T1 (cg-RX-API-DMAC7.html)
AU (1) AU765336B2 (cg-RX-API-DMAC7.html)
BG (1) BG65179B1 (cg-RX-API-DMAC7.html)
BR (1) BR9913982A (cg-RX-API-DMAC7.html)
CA (1) CA2340734C (cg-RX-API-DMAC7.html)
CZ (1) CZ300764B6 (cg-RX-API-DMAC7.html)
DE (1) DE69917074T2 (cg-RX-API-DMAC7.html)
DK (1) DK1147105T3 (cg-RX-API-DMAC7.html)
EE (1) EE04551B1 (cg-RX-API-DMAC7.html)
ES (1) ES2219091T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20010133B1 (cg-RX-API-DMAC7.html)
HU (1) HU226617B1 (cg-RX-API-DMAC7.html)
IL (1) IL141515A (cg-RX-API-DMAC7.html)
NO (1) NO317649B1 (cg-RX-API-DMAC7.html)
PL (1) PL196584B1 (cg-RX-API-DMAC7.html)
PT (1) PT1147105E (cg-RX-API-DMAC7.html)
RS (1) RS50129B (cg-RX-API-DMAC7.html)
RU (1) RU2222538C2 (cg-RX-API-DMAC7.html)
SI (1) SI1147105T1 (cg-RX-API-DMAC7.html)
SK (1) SK285582B6 (cg-RX-API-DMAC7.html)
UA (1) UA70340C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000035914A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200101182B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057664A1 (en) 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスOrphazyme Aps 酵素活性の調節因子としてのHsp70の使用
KR20110084514A (ko) 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 o-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2018215597A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
DE69628320D1 (de) * 1995-11-03 2003-06-26 Summit Packaging Systems Ltd Vorrichtung zum abgeben und füllen von beuteln an einem kassenplatz eines supermarkts
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
IL141515A0 (en) 2002-03-10
RS50129B (sr) 2009-03-25
EE200100188A (et) 2002-08-15
DE69917074D1 (de) 2004-06-09
SK2342001A3 (en) 2001-08-06
WO2000035914A1 (en) 2000-06-22
PL196584B1 (pl) 2008-01-31
US6384029B1 (en) 2002-05-07
BG105342A (en) 2001-12-29
EE04551B1 (et) 2005-10-17
ES2219091T3 (es) 2004-11-16
HRP20010133B1 (en) 2005-02-28
CZ300764B6 (cs) 2009-08-05
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
CA2340734C (en) 2008-10-21
BR9913982A (pt) 2001-06-12
AU765336B2 (en) 2003-09-18
JP2011201916A (ja) 2011-10-13
YU25001A (sh) 2004-07-15
HU226617B1 (en) 2009-04-28
PT1147105E (pt) 2004-07-30
KR100661774B1 (ko) 2006-12-28
ZA200101182B (en) 2002-02-12
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
JP5620340B2 (ja) 2014-11-05
JP2002532498A (ja) 2002-10-02
HRP20010133A2 (en) 2002-02-28
BG65179B1 (bg) 2007-05-31
DK1147105T3 (da) 2004-06-01
CZ20011550A3 (cs) 2001-08-15
SK285582B6 (sk) 2007-04-05
CA2340734A1 (en) 2000-06-22
PL346767A1 (en) 2002-02-25
IL141515A (en) 2005-09-25
AU1790600A (en) 2000-07-03
ATE266027T1 (de) 2004-05-15
KR20010073129A (ko) 2001-07-31
UA70340C2 (en) 2004-10-15
NO20012310L (no) 2001-05-10
NO317649B1 (no) 2004-11-29
EP1147105A1 (en) 2001-10-24
NO20012310D0 (no) 2001-05-10
HUP9802897A2 (hu) 2000-11-28
EP1147105B1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
DE69118889T2 (de) R(+)-terazosin
DE60003025T2 (de) Arylsulfonyle als faktor xa inhibitoren
JP5620340B2 (ja) 光学活性ピリジル−4h−1,2,4−オキサジアジン誘導体およびその血管疾患の治療における使用
DE60032905T2 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
JPWO1999020620A1 (ja) イソキノリン誘導体及び医薬
JP2011201916A5 (cg-RX-API-DMAC7.html)
PL197692B1 (pl) Chlorek 1-tlenku N-[2-hydroksy-3-(1-piperydynylo)propoksy]pirydyno-3-karboksyimidoilu, jego zastosowanie i środek farmaceutyczny
DE69500673T2 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
CH626344A5 (cg-RX-API-DMAC7.html)
DD277274A5 (de) Verfahren zur herstellung von alkoxybenzonitrilderivaten
EP0161599A2 (de) Neue Benzazepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0471388B1 (de) Mittel zur Behandlung der Herzinsuffizienz
DE3882476T2 (de) Pyridin- oder Pyridazinderivate als Kardioprotektiva und zur Behandlung von ischämischen Beschwerden und Herstellungsprozess.
DE69022442T2 (de) Aminoalkoxyphenyl-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen.
RU2333202C2 (ru) 2-(бутил-1-сульфониламино)-n-[1(r)-(6-метоксипиридин-3-ил)-пропил]бензамид, его применение в качестве лекарственного средства, а также содержащие его фармацевтические композиции
CH648022A5 (de) 1(2h)-isochinolon-verbindungen und saeureadditionssalze davon.
KR0148755B1 (ko) 신규 테트라하이드로이소퀴놀린계 화합물 및 그의 염
FR2462161A1 (fr) Compositions therapeutiques a base de composes azoiques
KR20030002304A (ko) 3-페닐-3,7-디아자비시클로[3.3.1]노난 화합물들과 이들의제조방법 및 이러한 화합물들을 포함하는 약제들
DE1929330C3 (de) l-Cinnamyl-4-(di-p-fluorbenzhydryl)piperazin, dessen therapeutisch wirksame Säureadditionssalze, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
AT360536B (de) Verfahren zur herstellung des neuen salpeter- saeureesters von n-(2-hydroxyaethyl)nicotinamid und von dessen salzen
DE2347757B2 (de) Basisch substituierte 1,4-benzodioxane und deren pharmakologisch nicht giftige saeureadditionssalze und verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
DE4220379A1 (de) Verwendung von kondensierten Bis-(3,4-dihydro-l-pyridinyl)methanen für die Herstellung von Mitteln für die Behandlung der Colitis Ulcerosa und des Morbus Crohn
JPH11130677A (ja) 細胞内カルシウム誘導性カルシウム放出チャンネル活性調節剤
DE3342628A1 (de) Verwendung von pyrazolonderivaten als lipoxygenasehemmer bei der therapie von ischaemien und herzrhythmusstoerungen, haut- und augenentzuendungen, sowie von rheumatischen, allergischen und asthmatischen erkrankungen, oedemen, lungenembolien, pulmonaler hypertension, schocklunge, sauerstoffintoxikation und ulcerationen, arzneimittel hierfuer und verfahren zu deren herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CYTRX CORP., LOS ANGELES, CALIF., US